Bicycle Therapeutics plc

These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.

Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.

What management said

“We are pleased with the continued progress made across our pipeline during the third quarter, as we advance nuzefatide pevedotin in the Phase 2 clinical trial in patients with recurrent pancreatic ductal adenocarcinoma and build our emerging pipeline of next-generation radioligands. We believe the FDA’s Orphan Drug Designation for nuzefatide in pancreatic cancer further supports our development strategy and underscores the significant unmet need in this patient population,”

Quoted verbatim from the release, and shown only when the filing attributes it to a named person.

How the share price reacted

Releases land before the open or after the close, so the window runs from the close before the report day to the close of the session after it — the reaction is inside it either way.

What Bicycle Therapeutics plc does

Bicycle Therapeutics is a clinical-stage pharmaceutical company developing a novel class of medicines, referred to as Bicycle ® molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycle molecules attractive candidates for drug development. The company is evaluating nuzefatide pevedotin, formerly BT5528, a Bicycle ® Drug Conjugate (BDC ® ) targeting EphA2, a historically undruggable target; a pipeline of other bicycle-based conjugate molecules, including Bicycle ® Radioconjugates (BRC ® ) for radiopharmaceutical use; zelenectide pevedotin (formerly BT8009), a BDC ® targeting Nectin-4, a well-validated tumor antigen; and, through various partnerships, is exploring the use of Bicycle ® technology to develop therapies for diseases in additional therapeutic areas. Bicycle Therapeutics is headquartered in Cambridge, UK, with many key functions and members of its leadership team located in Lexington, Mass.

The company’s own description, as it appears at the foot of the release.